Can we Boost Emicizumab Without Increasing Thrombosis Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn:
”Can we boost emicizumab without increasing thrombosis risk?
Emicizumab transformed hemophilia A care.
But breakthrough bleeding still happens, and treatment options remain imperfect.
A new RPTH study explores a provocative idea:
What if adding low-dose FIX plus FX together could safely enhance emicizumab-driven coagulation?
Here’s the key signal:
Combined FIX/FX supplementation restored coagulation potential to near-normal levels in vitro, in patient samples, and in hemophilia A mice.
Why this is biologically plausible:
- Emicizumab works by bridging FIXa and FX
- More FIX + FX to more ternary complex formation
- ~2× increase in FIX–emicizumab–FX complexes predicted
- Faster clot formation and reduced bleeding in vivo
- Thrombotic markers did not increase in animal models
Translation:
Rather than pushing bypassing agents harder, we may be able to optimize the emicizumab pathway itself.
Big questions for clinicians and researchers:
- Could FIX+FX become an alternative to rFVIIa for breakthrough bleeds?
- Could this strategy reduce treatment burden and dosing frequency?
- How do we balance enhanced hemostasis with real-world thrombosis risk?”
Title: Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
Authors: Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Find the Full Article on RPTH.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research
-
Oct 9, 2026, 23:38Micheal Avoseh: Exploring Nanoparticle-Based Therapies for Thrombosis and Vascular Inflammation
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation